Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics (NASDAQ:NEO) had its target price upped by research analysts at Needham & Company LLC from $14.00 to $15.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 31.12% from the stock’s previous close.

A number of other research analysts have also recently commented on NEO. Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a report on Tuesday, October 28th. Finally, TD Cowen restated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.13.

NeoGenomics Price Performance

NASDAQ:NEO opened at $11.44 on Tuesday. NeoGenomics has a 12-month low of $4.72 and a 12-month high of $13.74. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -13.00 and a beta of 1.58. The company’s 50-day moving average is $12.17 and its two-hundred day moving average is $10.11. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.NeoGenomics’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.04 EPS. Research analysts expect that NeoGenomics will post -0.2 EPS for the current year.

Insider Activity

In related news, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at $1,520,387.50. This represents a 15.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares of the company’s stock, valued at $372,996. This represents a 40.22% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. First Horizon Corp grew its position in NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after buying an additional 865 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of NeoGenomics by 42.5% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 997 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of NeoGenomics by 1.7% during the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock worth $858,000 after acquiring an additional 1,215 shares in the last quarter. Moody National Bank Trust Division grew its holdings in shares of NeoGenomics by 1.4% in the 3rd quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock worth $698,000 after acquiring an additional 1,227 shares during the last quarter. Finally, Amalgamated Bank grew its holdings in shares of NeoGenomics by 3.4% in the 3rd quarter. Amalgamated Bank now owns 37,965 shares of the medical research company’s stock worth $293,000 after acquiring an additional 1,255 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Key NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q4 results beat estimates: NeoGenomics reported $0.06 EPS vs. $0.04 expected and $190.17M revenue (vs. ~$188.3M est.), with revenue up ~10.6% YoY — proof of revenue momentum. Zacks Q4 Beat
• Positive Sentiment: Product tailwinds: Management emphasized traction in RaDaR ST and the PanTracer family (PanTracer Pro launch), which are positioned to accelerate genomic testing sales and could drive mid‑term revenue upside. SA: Revenue Target & Initiatives
• Neutral Sentiment: FY‑2026 revenue guide set to $793M–$801M (around consensus ~$796M) — guidance is basically in-line, not a clear upside surprise; the company’s EPS guidance was not a standout compared with expectations. SA: Guidance
• Neutral Sentiment: Investors can review the full earnings call and slide deck for color on commercialization cadence and margin levers — useful for modeling timing of expected benefits from new assays. Earnings Call Transcript
• Negative Sentiment: Despite the beat, shares fell (reports of a >5% drop) as traders reacted to mixed takeaways — a beat with in‑line guidance and continued negative margins often triggers profit‑taking. MSN: Shares Slide
• Negative Sentiment: Profitability concerns remain: NeoGenomics reported a negative net margin (~16%) and negative ROE (~3.4%); analysts still expect negative full‑year EPS, keeping investor focus on when margins will turn. BusinessWire: 2025 Results

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.